Despite the recent progress made in treating melanoma, an ongoing issue is the development of drug resistance to promising target-specific therapeutic strategies, resulting in treatment failure and subsequent death. A new study from Boston University School of Medicine (BUSM) has discovered that a drug (YK-4-279) that was previously created to target one specific type of protein has much broader use against a family of proteins that act to promote melanoma.
